US$ 21.29
dual gip and glp-1 receptor agonist Targeting GLP-1, & GCG in Obesity Type 2 Diabetes Research GIP (Gastric Inhibitory Polypeptide) Assay
Description
Some employers have begun to include obesity medications as part of wellness initiatives, recognizing their potential to reduce long-term healthcare costs

Arterioscler Thromb

Trulicity (dulaglutide) product information

GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions

Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study , (December 18, 2023)

has hypertension thats managed on amlodipine
